Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next.
Phase 2 clinical trials using daily injectable glucagon-like peptide-1 receptor agonists as adjunct therapy in type 1 diabetes showed promising signals for efficacy on glycemic control and weight. These effects were confirmed in larger phase 3 trials but accompanied by safety issues including hypoglycemia and ketosis. Of note, these trials were conducted before the availability of widespread continuous glucose monitoring (CGM) and used simple one size fits all rules for insulin dose titration. Attention has moved on to weekly injectable agents at present, with more individualized insulin titration and guided by CGM.